Abstract
To search for anti-cancer agents, a screening system for Ras signal inhibitors was developed using a NIH3T3 cell line with an introduced reporter gene which is controlled by the Ras-responsive element (RRE). With this screening system, malolactomycin D was identified as a selective inhibitor of transcription from the RRE. This compound was found to preferentially inhibit the anchorage-independent growth rather than the anchorage-dependent growth of Ras-transformed NIH3T3 cells. The expression of matrix metalloproteinases MMP-1 and MMP-9, which have RRE in their promoters, were reduced by treatment with malolactomycin D at the translational and transcriptional levels. Analysis of the activity of mitogen-activated protein (MAP) kinases, which play important roles in transduction of the Ras signal, showed that malolactomycin D inhibits the activation of p38 MAP kinase and Jun N-terminal-kinase (JNK) but not extracellular signal-regulated kinase 1 or 2 (ERK1 or 2). These findings suggest that by inhibiting the pathway that leads to the activation of p38 MAP kinase and JNK, malolactomycin D suppresses the expression of MMPs. Since MMPs play important roles in metastasis and maintenance of the microenvironment of tumor cells, both of which facilitate tumor growth, the inhibition of MMPs by malolactomycin D is believed to contribute to its ability to inhibit Ras-mediated tumorigenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Aho S, Rouda S, Kennedy SH, Qin H, Tan EM . 1997 Eur. J. Biochem. 247: 503–510
Behre G, Smith LT, Tenen DG . 1999 BioTechniques 26: 24–28
Bortner DM, Langer SJ, Ostrowski MC . 1993 Crit. Rev. Oncog. 4: 137–160
Bos JL . 1989 Cancer Res. 49: 4682–4689
Brauchle M, Gluck D, Di Podova F, Han J, Gram H . 2000 Exp. Cell. Res. 258: 135–144
Burke LJ, Baniahmad A . 2000 FASEB J. 14: 1876–1888
Buttice G. Duterque-Coquillaud M, Basuyaux JP, Carrere S, Kurkinen M, Stehelin D . 1996 Oncogene 13: 2297–2306
Chomczynski P, Sacchi N . 1987 Anal. Biochem. 162: 156–159
Corcoran ML, Hewitt RE, Kleiner Jr DE, Stetler-Stevenson WG . 1996 Enzyme Protein 49: 7–19
Corominas M, Sloan SR, Leon J, Kamino H, Newcomb EW, Pellicer A . 1991 Environ. Health Perspect. 93: 19–25
Curran S, Murray GI . 1999 J. Pathol. 189: 300–308
Futamura M, Monden Y, Okabe T, Fujita-Yoshigaki J, Yokoyama S, Nishimura S . 1995 Oncogene 10: 1119–1123
Gardner AM, Vaillancourt RR, Johnson GL . 1993 J. Biol. Chem. 268: 17896–17901
Goustin AS, Leof EB, Shipley GD, Moses HL . 1986 Cancer Res. 46: 1015–1029
Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D . 1996 J. Biol. Chem. 271: 10672–10680
Heussen C, Dowdle EB . 1980 Anal. Biochem. 102: 196–202
Himelstein BP, Lee EJ, Sato H, Seiki M, Muschel RJ . 1998 Clin. Exp. Metastasis 16: 169–177
Hodge C, Liao J, Stofega M, Guan K, Carter-Su C, Schwartz J . 1998 J. Biol. Chem. 273: 31327–31336
Imler JL, Schatz C, Wasylyk C, Chatton B, Wasylyk B . 1988 Nature 332: 275–278
Johansson N, Ala-aho R, Uitto V, Grenman R, Fusenig NE, Lopez-Otin C, Kahari VM . 2000 J. Cell. Sci. 113: 227–235
Kleiner DE, Stetler-Stevenson WG . 1999 Cancer Chemother. Pharmacol. 43: S42–S51
Kuo MH, Allis CD . 1998 BioEssays 20: 615–626
Newberry EP, Willis D, Latifi T, Boudreaux JM, Towler DA . 1997 Mol. Endocrinol. 11: 1129–1144
Newbold RF, Overell RW . 1983 Nature 304: 648–651
Nishimura S, Sekiya T . 1987 Biochem. J. 243: 313–327
Price MA, Hill C, Treisman R . 1996 Philos. Trans. R. Soc. Lond. B. Biol. Sci. 351: 551–559
Qin H, Sun Y, Benveniste EN . 1999 J. Biol. Chem. 274: 29130–29137
Reddy MA, Langer SJ, Colman MS, Ostrowski MC . 1992 Mol. Endocrinol. 6: 1051–1060
Rowinsky EK, Windle JJ, Von Hoff DD . 1999 J. Clin. Oncol. 17: 3631–3652
Simon C, Geopfert H, Boyd D . 1998 Cancer Res. 58: 1135–1139
Soga S, Kozawa T, Narumi H, Akinaga S, Irie K, Matsumoto K, Sharma SV, Nakano H, Mizukami T, Hara M . 1998 J. Biol. Chem. 273: 822–828
Spencer JA, Major ML, Misra RP . 1999 Mol. Cell Biol. 19: 3977–3988
Tanaka Y, Yoshida H, Enomoto Y, Shiomi K, Shinose M, Takahashi Y, Liu JR, Omura S . 1997 J. Antibiot. (Tokyo) 50: 194–200
Van Aelst L, Barr M, Marcus S, Polverino A, Wigler M . 1993 Proc. Natl. Acad. Sci. USA 90: 6213–6217
Watabe T, Yoshida K, Shindoh M, Kaya M, Fujikawa K, Sato H, Seiki M, Ishii S, Fujinaga K . 1998 Int. J. Cancer 77: 128–137
Westermarck J, Kahari VM . 1999 FASEB J. 13: 781–792
White LA, Maute C, Brinckerhoff CE . 1997 Connect. Tissue Res. 36: 321–335
Winitz S, Russell M, Qian NX, Gardner A, Dwyer L, Johnson GL . 1993 J. Biol. Chem. 268: 19196–19199
Zhao A, Lee SH, Mojena M, Jenkins RG, Patrick DR, Huber HE, Goetz MA, Hensens OD, Zink DL, Vilella D, Dombrowski AW, Lingham RB, Huang L . 1999 J. Antibiot. (Tokyo) 52: 1086–1094
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Futamura, M., Kamiya, S., Tsukamoto, M. et al. Malolactomycin D, a potent inhibitor of transcription controlled by the Ras responsive element, inhibits Ras-mediated transformation activity with suppression of MMP-1 and MMP-9 in NIH3T3 cells. Oncogene 20, 6724–6730 (2001). https://doi.org/10.1038/sj.onc.1204878
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204878
Keywords
This article is cited by
-
Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains
Cell Communication and Signaling (2014)
-
Strategies for MMP inhibition in cancer: innovations for the post-trial era
Nature Reviews Cancer (2002)